High-affinity immunoglobulin epsilon receptor I (FcεRI) complexed with Immunoglobulin E (IgE) (FcεRI-IgE complex)

The complex formed by the binding of Immunoglobulin E (IgE) to the high-affinity IgE receptor (FcεRI) on mast cells and basophils is the central molecular trigger for Type I hypersensitivity reactions (StatPearls, Type I Hypersensitivity). In sensitized individuals, IgE antibodies specific to environmental allergens occupy the FcεRI receptors, effectively priming the effector cells for an immune response. When an allergen subsequently encounters these cells, it cross-links the bound IgE molecules, inducing a conformational change in the receptor that activates intracellular signaling pathways, most notably involving Bruton's tyrosine kinase (BTK) (PubMed: 29330014). This activation leads to the rapid degranulation and release of inflammatory mediators like histamine, leukotrienes, and cytokines, resulting in clinical symptoms ranging from mild rhinitis to life-threatening anaphylaxis. Therapeutic interventions like omalizumab work by binding to the Fc region of free IgE at the same site required for FcεRI binding, thereby preventing the formation of the complex and gradually downregulating receptor expression on the cell surface (PubMed: 12756130). Newer small-molecule inhibitors target the downstream signaling of the complex to provide relief in conditions like chronic spontaneous urticaria and allergic asthma (ClinicalTrials.gov, NCT04109313).

Other names

Fc epsilon RI-IgE complexHigh-affinity IgE receptor complexIgE-FcεRI receptor complexSensitized FcεRI

Prevention of IgE-FcεRI binding by sequestering free IgE; downregulation of surface FcεRI expression; inhibition of downstream signaling via Bruton's tyrosine kinase (BTK) inhibition.